Search 

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Simcere Pharmaceutical Group is a leading Chinese pharmaceutical company with full capability in discovery, development, manufacturing and commercialization. Simcere is actively looking for innovative drug candidates in multiple therapeutic areas. Simcere of America is a subsidiary of Simcere Pharmaceutical Group.

SYNSIGHT developed the first drug discovery platform combining cell-based microscopy that train AI models, to generate new chemical entities. Your benefits will be to increase the productivity of your R&D and secure your drug discovery programs.

Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.

We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …

VC investment focus on healthy care

A publicly-traded bioceutical research, development and marketing firm with over 40 products backed by a combined $68 million in research and development and clinical studies. TRICCAR solutions support health challenges affecting over 6 billion people worldwide, beginning with four products to be introduced in 2021:

AVL™ - Antiviral immunity support
Global audience size: 6.2+ billion

CAL™ - Calcium deficiency
Global audience size: 6+ billion

OFF™ - Weight and obesity management
Global audience size: 1+ billion

CLM™ - Menopausal support
Global audience size: 500+ million

Having met 85%> effectiveness in placebo-based, double-blind studies, TRICCAR’s products are ready for market introduction as over-the-counter, direct-to-consumer bioceutical products. An additional 8 products will undergo Food and Drug Administration (FDA) approval. Our initial four products are targeted towards women, ages 25-65, yet appeal to all demographics and genders.

We sell via our patented and patent-pending direct-to-consumer marketing technologies that have historically generated $18 in revenue for every $1 spent compared to industry averages of $2 for every $1 spent. We add to these efforts with retail (ex. Walgreens, CVS, COSTCO, etc.) and online marketplaces (ex. Walmart.com, Amazon.com), and a 130,000 physician/chiropractor network.

Our Series B Convertible Preferred PIPE offering minimizes investor risk while providing significant potential upside. TRICCAR anticipates 3-year total revenue to exceed $163.2 million. Based on comparable price/sales valuations, this could indicate a market cap of approximately $403.5 million at time of conversion.

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Gene Therapy company delivering Intrabodies with AAV delivery targeting misfolded proteins in neurodegenerative diseases. INT41 for Huntington’s Disease is our flagship product with successful results in cell based and animal models for Huntington's disease with additional indications. INT41 has Orphan Designation from the FDA.

Our platform selects Intrabodies that target novel intracellular mutations or stabilize refolding and can be applied to multiple therapeutic areas. 

healthcare VC

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services